At a glance · for buyers and watchdogs
Ferndale Pharmaceuticals Ltd has won £35.8m across 2 public-sector buyers, with 4 live contracts.
Why: top buyer NHS England at 100% · 1 active risk flag · 0 modifications.
ESG & policies vault · 0/5
Key governance & sustainability policies. Published documents link out; missing ones are greyed.
Capabilities
What this supplier does, where they sit, who they sell to.
Service tags, sectors served and target geographies appear here once a supplier verifies ownership of this profile.
- NHS Framework Agreement for Branded medicines - National
Case studies
Delivery stories the supplier has published, with sector and outcome.
No case studies yet
Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.
Buyer references
Named public-sector contacts who have agreed to act as a reference.
No buyer references yet
Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.
Accreditations & memberships
Independently issued. Verification dates cross-checked against issuer registers.
No accreditations recorded
B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.
KPI performance
Delivery, budget and satisfaction scores reported quarterly by buyers.
No verified KPI scores yet
Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.
Contracts · 4 live · 2 historic
Pulled from Contracts Finder & Find a Tender. Most recent first.
| Title | Buyer | CPV | Awarded | Value | Term | Status |
|---|---|---|---|---|---|---|
| NHS England | 33600000 | 01 May 2024 | £11.2m | 4 yrs | Live | |
| NHS England | 33600000 | 01 May 2022 | £6.1m | 2 yrs | Closed | |
| NHS England | 33600000 | 01 May 2019 | £18.5m | 2 yrs | Closed | |
| NHS England | 33600000 | — | — | — | Live | |
| NHS England | — | — | — | — | Live | |
| The NHS Commissioning Board (operating under the name of NHS England) | 33600000 | — | — | — | Live |
Top buyers · 2 buyers · top 3 = 100%
Share of awarded value. Concentration fires above 40% for any single buyer.
Geography
Distribution of awarded value by buyer region.
Peers
Suppliers with overlapping CPVs & buyers (last 24m). Ferndale Pharmaceuticals Ltd highlighted.
| Supplier | SME? | Awarded · 24m | Contracts |
|---|---|---|---|
| Yes | £121.0m | 22 | |
| Yes | £117.6m | 18 | |
| Yes | £95.2m | 12 | |
| Yes | £72.5m | 12 | |
| Yes | £71.2m | 21 | |
FP Ferndale Pharmaceuticals Ltd | Yes | — | — |
Red flags · 1 active
Automated scan of Companies House status, charges and insolvency records.
Compliance scorecard
Derived from Companies House filings — not a full supplier-assurance check.
Modifications
Variations to awarded contracts logged under Procurement Act 2023 s.74.
No modifications recorded
No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.
News mentions
UK trade press & nationals, matched to this supplier.
No news mentions found
We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.
Companies House
Live sync — registered details, directors, PSC and SIC codes.
Registered details
- Company no.
- 04720051
- Status
- Active
- Type
- Private limited
- Incorporated
- 02 Apr 2003
- Reg. office
- Unit 740 Street 2, Thorp Arch Estate, Wetherby, West Yorkshire, LS23 7FX
- SIC codes
- 20420 · 21200
- Last accounts
- 31 Dec 2024
- Next accounts due
- 30 Sept 2026
Directors & PSC
- STEIN, Christopher — directorAppointed 03 Mar 2019
- DAVIES, Sem Lloyd — directorAppointed 25 May 2011
- MCMILLAN II, James Thayer — directorAppointed 09 Sept 2003
- WOOD, Roisin — secretaryAppointed 15 Jul 2003
- BLOXHAM, Roger Mark — directorAppointed 15 Jul 2003
- Mr Roger Mark Bloxham — person with significant controlownership of shares 25 to 50 percent
- Ferndale Pharma Group Inc — person with significant controlownership of shares 50 to 75 percent
Financial
Filed accounts from Companies House.
No financial filings on record
Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.
Org tree
Group structure and ownership.
Independent. No parent company or subsidiaries recorded at Companies House for this entity.
Social value
Commitments mapped to the Government Social Value Model themes.
No social-value commitments yet
Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.